Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

https://is1-ssl.mzstatic.com/image/thumb/Podcasts221/v4/66/77/29/667729bb-b72a-4abb-8a66-d0f293806148/mza_16977989797155034764.jpg/600x600bb.jpg

Skinfluenced - The Skin Podcast

15 episodes

6 days ago

🧴 Harnessing the power of technology, Skinfluenced: The Skin Podcast keeps you plugged into the fast-moving worlds of dermatology, wellness, and aesthetics. From the latest journal articles and groundbreaking studies, to new FDA approvals, new product launches, and clinical insights—this podcast is your go-to source for evidence-based updates that matter. Whether you're a seasoned provider or just dipping your toe in the sand, you'll stay one step ahead of the trends, the science, and your skin. Disclaimer: All content is for educational purposes only and does not constitute medical advice.

Medicine

Health & Fitness

RSS

All content for Skinfluenced - The Skin Podcast is the property of Skinfluenced - The Skin Podcast and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.

Medicine

Health & Fitness

https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/44144955/44144955-1762876961187-f0ff516dd1553.jpg

Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

Skinfluenced - The Skin Podcast

13 minutes 55 seconds

6 days ago

Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

Disclaimer: This podcast is not sponsored by or associated with any of the products mentioned in today's episode.

Episode 15 Drop: Atopic Dermatitis Breakthrough: Precision Treatment and the Promise of AdvanceAD-Tx™

In this episode of Skinfluenced: The Skin Podcast, we explore a groundbreaking advancement in the management of moderate-to-severe atopic dermatitis (AD). Castle Biosciences’ new AdvanceAD-Tx™ test, launched THIS MONTH, introduces precision medicine to dermatology with a 487-gene expression profile (GEP) that decodes each patient’s unique immune biology. By classifying results into different profile groups, clinicians can now identify which patients are more likely to respond to specific systemic therapies—before treatment even begins.

We're breaking down:

The IDENTITY study which showed how patients can now get EASI-90 nearly 4X faster
How this innovation could transform treatment selection, improve patient outcomes, and redefine the role of molecular testing in dermatology.

⚠️ Educational purposes only. Not medical advice.

Link to Source(s):

Castle Biosciences, Inc. Castle Biosciences Launches AdvanceAD-Tx™ to Help Guide Systemic Treatment Decision Making in Patients with Moderate-to-Severe Atopic Dermatitis. Accessed November 11, 2025. https://ir.castlebiosciences.com/news/news-details/2025/Castle-Biosciences-Launches-AdvanceAD-Tx-to-Help-Guide-Systemic-Treatment-Decision-Making-in-Patients-with-Moderate-to-Severe-Atopic-Dermatitis/default.aspx

Chiesa Fuxench, Zelma C., et al. Atopic Dermatitis in America Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic Dermatitis in the US Adult Population. Journal of Investigative Dermatology. 2019; 139: 583–590.

Silverberg, Jonathan I., et al. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study. Annals of Allergy, Asthma & Immunology. 2018; 121(3): 340-347.

Silverberg, Jonathan I., et al. The 487-gene expression profile test guides systemic therapy selection to improve outcomes for patients with atopic dermatitis: Results from a prospective, multi-center trial. Castle Biosciences AdvanceAD-Tx™ Launch Slide Deck. November 2025.

The Derm Digest. Castle Biosciences Rolls Out AdvanceAD-Tx. Accessed November 11, 2025. https://thedermdigest.com/castle-biosciences-rolls-out-advancead-tx/?utm_source=Klaviyo&utm_medium=campaign&_kx=LStbfMDiK_dFORiyt1p_kkItQ6IXDv9wQWWp60o95yV8qS2-9Wbebg-OUZpTxSvC.TYhhHR